Bausch Health Companies Inc. Accounts Receivable, Allowance for Credit Loss, Recovery
Bausch Health Companies Inc. (BHC) reported Accounts Receivable, Allowance for Credit Loss, Recovery of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries · last filed 2025-05-01
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2025-03-31 was $0.00.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2024-12-31 was $3.00M.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2024-09-30 was $0.00.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for the quarter ending 2024-06-30 was $0.00.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for fiscal 2024 was $3.00M, a 0.00% change from fiscal 2023.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for fiscal 2023 was $3.00M, a 50.00% increase from fiscal 2022.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for fiscal 2022 was $2.00M, a 0.00% change from fiscal 2021.
- Bausch Health Companies Inc. accounts receivable, allowance for credit loss, recovery for fiscal 2021 was $2.00M, a 33.33% decline from fiscal 2020.
| Period end | Accounts Receivable, Allowance for Credit Loss, Recovery 3 month | Accounts Receivable, Allowance for Credit Loss, Recovery 6 month | Accounts Receivable, Allowance for Credit Loss, Recovery 9 month | Accounts Receivable, Allowance for Credit Loss, Recovery 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $3.00M derived: sum of 2 quarters · filed 2025-05-01 | $3.00M derived: sum of 3 quarters · filed 2025-05-01 | $3.00M derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.00M derived: sum of 2 quarters · filed 2025-02-20 | $3.00M derived: sum of 3 quarters · filed 2025-02-20 | $3.00M 10-K · filed 2025-02-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2025-05-01 | $0.00 derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2025-05-01 | $0.00 derived: sum of 3 quarters · filed 2025-05-01 | $0.00 derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $3.00M 10-K · filed 2025-02-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $3.00M 10-Q · filed 2024-10-31 | $1.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.00M 10-Q · filed 2024-08-01 | $1.00M derived: sum of 3 quarters · filed 2025-02-20 | $2.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $3.00M 10-Q · filed 2024-05-02 | $1.00M derived: sum of 2 quarters · filed 2025-02-20 | $2.00M derived: sum of 3 quarters · filed 2025-02-20 | $2.00M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$1.00M derived: sum of 2 quarters · filed 2025-02-20 | -$1.00M derived: sum of 3 quarters · filed 2025-02-20 | $2.00M 10-K · filed 2025-02-20 |
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.00M derived: sum of 2 quarters · filed 2023-11-02 | $4.00M 10-Q · filed 2023-11-02 | $4.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.00M 10-Q · filed 2023-08-03 | $3.00M derived: sum of 3 quarters · filed 2024-02-22 | $4.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $3.00M 10-Q · filed 2023-05-04 | $3.00M derived: sum of 2 quarters · filed 2024-02-22 | $4.00M derived: sum of 3 quarters · filed 2024-02-22 | $5.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.00M derived: sum of 2 quarters · filed 2024-02-22 | $2.00M derived: sum of 3 quarters · filed 2024-02-22 | $2.00M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.00M derived: sum of 2 quarters · filed 2022-11-03 | $2.00M 10-Q · filed 2022-11-03 | $4.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.00M 10-Q · filed 2022-08-09 | $3.00M derived: sum of 3 quarters · filed 2023-02-23 | $3.00M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $2.00M derived: sum of 2 quarters · filed 2023-02-23 | $2.00M derived: sum of 3 quarters · filed 2023-02-23 | |
| 2020-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.00M derived: sum of 2 quarters · filed 2023-02-23 | $3.00M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.00M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $1.00M 10-Q · filed 2021-08-03 | |||
| 2019-12-31 | $1.00M 8-K · filed 2022-05-11 | |||
| 2018-12-31 | $2.00M 8-K · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |